BPC-157 has been proposed as a potential treatment of physiologically based illnesses that disproportionately affect certain patient populations, such as the COVID-19 illness, as it improves vascular integrity and immune response, reduces the pro-inflammatory profile, has an anti-inflammatory effect, and reduces the lethality of critical COVID-19 illnesses [3]
Common Uses Torn or inflamed tendons (e.g., rotator cuff, patellar tendonitis) Muscle tears and post-surgical repair Ligament sprains (ankle, wrist, knee) Intestinal damage or inflammation (IBD, IBS, ulcers) Stacking in peptide recovery protocols with TB-500 or growth hormone secretagogues Typical Dosage and Administration Dose : 200500 mcg per day Frequency : 12 times daily Route : Subcutaneous injection (often near the injury site), or oral for digestive issues Duration : Typically 24 weeks, depending on severity BPC-157 is often used in conjunction with physical therapy or training rehab programs for synergistic results
and Smith, V.J., Biochem
Sobo help me decide whether KPV is appropriate
They are coming off the Category 2 restricted list effective April 23, 2026, with PCAC review of their compounding eligibility scheduled for July 23-24, 2026
The compounded semaglutide with B12 dosage charts use the same B12 concentrations as tirzepatide formulations, so the color ranges are essentially identical